528 related articles for article (PubMed ID: 23271562)
1. Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?
Kumar V
Purinergic Signal; 2013 Jun; 9(2):145-65. PubMed ID: 23271562
[TBL] [Abstract][Full Text] [Related]
2. Adenosine: an endogenous modulator of innate immune system with therapeutic potential.
Kumar V; Sharma A
Eur J Pharmacol; 2009 Aug; 616(1-3):7-15. PubMed ID: 19464286
[TBL] [Abstract][Full Text] [Related]
3. Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities.
Vaupel P; Multhoff G
Strahlenther Onkol; 2016 May; 192(5):279-87. PubMed ID: 26961686
[TBL] [Abstract][Full Text] [Related]
4. Extracellular ATP inhibits IL-1-induced MMP-1 expression through the action of CD39/nucleotidase triphosphate dephosphorylase-1 on human gingival fibroblasts.
Nemoto E; Gotoh K; Tsuchiya M; Sakisaka Y; Shimauchi H
Int Immunopharmacol; 2013 Nov; 17(3):513-8. PubMed ID: 23941770
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the N
Jackson EK; Gillespie DG; Cheng D; Mi Z; Menshikova EV
Purinergic Signal; 2020 Jun; 16(2):187-211. PubMed ID: 32367441
[TBL] [Abstract][Full Text] [Related]
6. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.
Stagg J; Golden E; Wennerberg E; Demaria S
Sci Immunol; 2023 Jul; 8(85):eabq3015. PubMed ID: 37418547
[TBL] [Abstract][Full Text] [Related]
7. Extracellular ATP and adenosine: The Yin and Yang in immune responses?
Faas MM; Sáez T; de Vos P
Mol Aspects Med; 2017 Jun; 55():9-19. PubMed ID: 28093236
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
[TBL] [Abstract][Full Text] [Related]
11. ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity.
Silva-Vilches C; Ring S; Mahnke K
Front Immunol; 2018; 9():2581. PubMed ID: 30473700
[TBL] [Abstract][Full Text] [Related]
12. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.
Kazemi MH; Raoofi Mohseni S; Hojjat-Farsangi M; Anvari E; Ghalamfarsa G; Mohammadi H; Jadidi-Niaragh F
J Cell Physiol; 2018 Mar; 233(3):2032-2057. PubMed ID: 28233320
[TBL] [Abstract][Full Text] [Related]
13. Crowding within synaptic junctions influences the degradation of nucleotides by CD39 and CD73 ectonucleotidases.
Rahmaninejad H; Pace T; Chun BJ; Kekenes-Huskey PM
Biophys J; 2022 Jan; 121(2):309-318. PubMed ID: 34922916
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the T Cell Response by CD39.
Takenaka MC; Robson S; Quintana FJ
Trends Immunol; 2016 Jul; 37(7):427-439. PubMed ID: 27236363
[TBL] [Abstract][Full Text] [Related]
15. Extracellular adenosine metabolism in immune cells in melanoma.
Umansky V; Shevchenko I; Bazhin AV; Utikal J
Cancer Immunol Immunother; 2014 Oct; 63(10):1073-80. PubMed ID: 24756420
[TBL] [Abstract][Full Text] [Related]
16. Adenosine Signaling in the Tumor Microenvironment.
Antonioli L; Fornai M; Pellegrini C; D'Antongiovanni V; Turiello R; Morello S; Haskó G; Blandizzi C
Adv Exp Med Biol; 2021; 1270():145-167. PubMed ID: 33123998
[TBL] [Abstract][Full Text] [Related]
17. Targeting adenosine and regulatory T cells in cancer immunotherapy.
Churov A; Zhulai G
Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
[TBL] [Abstract][Full Text] [Related]
18. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
Kumar M; Lowery R; Kumar V
SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
[TBL] [Abstract][Full Text] [Related]
19. Elevated CD39+T-Regulatory Cells and Reduced Levels of Adenosine Indicate a Role for Tolerogenic Signals in the Progression from Moderate to Severe COVID-19.
Elsaghir A; El-Sabaa EMW; Zahran AM; Mandour SA; Salama EH; Aboulfotuh S; El-Morshedy RM; Tocci S; Mandour AM; Ali WE; Abdel-Wahid L; Sayed IM; El-Mokhtar MA
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139439
[TBL] [Abstract][Full Text] [Related]
20. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X; Xie L
J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
